Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
Fauchais
A L
AL
Prey
S
S
Ouatara
B
B
Vidal
E
E
Sparsa
A
A
D000328:Adult; D000794:Angiokeratoma / Q000188:drug therapy*; D056947:Enzyme Replacement Therapy / Q000379:methods*; D000795:Fabry Disease / Q000188:drug therapy*; D006801:Humans; D007527:Isoenzymes / Q000627:therapeutic use*; D008297:Male; D012074:Remission Induction; D012611:Scrotum; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D000519:alpha-Galactosidase / Q000627:therapeutic use*
D007527:Isoenzymes; D000519:alpha-Galactosidase; C459420:agalsidase beta